Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Butterfly Network (BFLY) Delivers Strong Q3 with Record Margins and Raised 2026 Outlook

Butterfly Network (BFLY) Delivers Strong Q3 with Record Margins and Raised 2026 Outlook

Key Takeaways

  • Butterfly Network reported third quarter 2026 revenue of $32.6 million, up 52% year over year and about 9% above the top end of its own guidance.
  • GAAP net loss narrowed to $12.8 million, or $0.05 per share, compared with a $34.0 million loss, or $0.13 per share, a year earlier.
  • The company posted its highest gross margin in its history at 73.0%, while adjusted EBITDA loss improved to just $1.2 million.
  • Butterfly raised its full-year 2026 revenue guidance to $123 million to $126 million, representing roughly 26% to 29% growth.
  • Butterfly Embedded revenue surged more than 1,000% to $11.1 million, driven by the Midjourney partnership and new partners including Merge Labs and Bridge Neurotech.
  • Shares rose about 5.8% on the day of the report as investors reacted to the beat and raised outlook.

Earnings Context and Why It Matters

Butterfly Network, a pioneer in semiconductor-based ultrasound devices, cloud software, and artificial intelligence, has been shifting from a hardware-focused point-of-care ultrasound provider toward a broader platform built around enterprise software and high-growth Embedded partnerships. The third quarter of 2026 served as an important checkpoint for that transition, with investors seeking confirmation that recent revenue growth and margin improvements could hold up. Earlier periods had shown solid U.S. gains and shrinking losses, yet the core POCUS business had expanded more gradually. This quarter stood out because it tested whether the Embedded pipeline and enterprise momentum could counter international softness and keep the company aligned with its path to profitability.

Reported Results

Butterfly Network reported third quarter 2026 revenue of $32.6 million, a 52% increase from $21.5 million a year earlier and ahead of the roughly $28.4 million consensus estimate. Net loss was $12.8 million, or $0.05 per share, versus a $34.0 million loss, or $0.13 per share, in the prior-year period. Adjusted loss per share came in at about $0.01, better than the roughly $0.04 loss analysts had projected. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Gross margin reached a record 73.0%, up 913 basis points year over year, helped by a higher mix of Embedded revenue. Adjusted EBITDA loss narrowed to $1.2 million, an 85% improvement from $8.1 million a year earlier. U.S. revenue climbed 71% to $27.5 million, while international revenue declined 5% to $5.1 million amid deal timing shifts. Core POCUS revenue rose 5% to $21.5 million, while Embedded revenue jumped over 1,000% to $11.1 million. Cash and equivalents stood at $122.3 million at quarter end.

Management raised full-year 2026 revenue guidance to $123 million to $126 million and issued fourth-quarter revenue guidance of $31 million to $34 million, with an adjusted EBITDA loss of $3 million to $6 million. The company also highlighted five seven-figure and ten six-figure TCV enterprise deals.

Market Reaction and Investor Sentiment

Investors responded favorably to the report, pushing shares up roughly 5.8% on the day to close near $7.81. The combination of a revenue beat, a record gross margin, a sharply narrower adjusted EBITDA loss, and a full-year guidance raise helped refresh sentiment after a period of choppier short-term trading. The market’s positive tone was tempered somewhat by the fourth-quarter guidance range, which implied a potential sequential revenue dip, and by the disclosure of a new $150 million shelf registration and ATM program, which some investors view as a potential dilution risk. Still, the dominant interpretation was that Butterfly’s Embedded strategy is scaling faster than expected while the enterprise pivot continues to firm up the core business.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether BFLY can sustain its Embedded momentum while stabilizing international results. Management signaled expectations for improved fourth-quarter and 2027 performance, but Embedded revenue remains lumpy because it is tied to partner program timing and development milestones. Concentration risk around a few large partners, including Midjourney, is another factor to monitor, particularly since management does not break out individual partner contributions.

On the core side, the company’s enterprise strategy is gaining traction through multi-year contracts and Compass AI adoption. The FedRAMP authorization achieved during the quarter opens access to the federal government, the largest healthcare purchaser, and management pointed to a growing pipeline. The Home & Community Care program has moved into execution, with initial revenue expected in the fourth quarter and more meaningful contribution anticipated by 2028.

Key variables to track in coming quarters include gross margin durability, cash burn, the pace of international recovery, and whether enterprise deals layer into a steadier revenue base. The new shelf registration and ATM program also bear watching, as any equity issuance could affect share count. As always, these items should be evaluated alongside broader demand for portable, AI-enabled ultrasound across hospital, clinic, and out-of-hospital settings.

Exploring AI Tools for Earnings Analysis

In my own workflow I frequently turn to Tickeron’s AI-powered tools to cross-check earnings data and spot comparable setups across the medtech sector. The AI Screener lets me filter quickly on fundamentals, growth rates, and technical signals, which helps put a quarter like this one in broader context without spending hours on manual screens. It has become a regular part of how I review names that are transitioning business models.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BFLY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BFLY sees MACD Histogram just turned negative

BFLY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 41 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BFLY as a result. In 73 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BFLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for BFLY entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where BFLY advanced for three days, in 187 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.956) is normal, around the industry mean (4.142). P/E Ratio (-21.966) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (16.556) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. BFLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BFLY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
1600 District Avenue
Phone
+1 781 557-4800
Employees
220
Web
https://www.butterflynetwork.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.